title: Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
abstract: To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with methotrexate (MTX) in patients with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to MTX.
  
  
  
  In this multinational, phase IIb, randomized, double-blind, placebo-controlled, dose-ranging trial, patients with RA (n = 378) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg plus MTX, or matching placebo plus MTX once daily for 12 weeks. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at week 12.
  
  
  
  ACR20 response rates at week 12 were 43.9%, 61.5% (P < 0.05 versus placebo), 46.4%, 57.7%, and 44.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, respectively. Significant decreases from baseline in the Disease Activity Score in 28 joints using the C-reactive protein level were seen in the peficitinib 50 mg (P < 0.05) and 150 mg (P < 0.01) groups compared with placebo at week 12. Overall, the incidence of adverse events (AEs) was similar between peficitinib and placebo. The most common AEs were urinary tract infection (n = 22 [6%]), upper respiratory tract infection (n = 16 [4%]), and diarrhea (n = 16 [4%]). There were 3 cases of herpes zoster infection (2 in the peficitinib 100 mg group and 1 in the 150 mg group) and 2 cases of serious infection (viral infection in the peficitinib 100 mg group and erysipelas in the 150 mg group).
  
  
  
  The ACR20 response rate in the group receiving peficitinib 50 mg plus MTX was significantly different compared with the rate in patients receiving placebo, but there were no apparent dose-dependent responses, and the placebo response rate was high. Peficitinib plus MTX in patients with moderate-to-severe RA was well tolerated, with limited safety signals emerging.
authors.affiliation: Altoona Center for Clinical Research, Duncansville, Pennsylvania.
authors.forename: A J
authors.initials: AJ
authors.lastname: Kivitz
authors.affiliation: Hospital Civil de Guadalajara, Guadalajara, Mexico.
authors.forename: S R
authors.initials: SR
authors.lastname: Gutierrez-Ureña
authors.affiliation: Arthritis Associates, Orlando, Florida.
authors.forename: J
authors.initials: J
authors.lastname: Poiley
authors.affiliation: Stanford University, Palo Alto, California.
authors.forename: M C
authors.initials: MC
authors.lastname: Genovese
authors.affiliation: Astellas Pharma Global Development, Northbrook, Illinois.
authors.forename: R
authors.initials: R
authors.lastname: Kristy
authors.affiliation: Astellas Pharma Global Development, Northbrook, Illinois.
authors.forename: K
authors.initials: K
authors.lastname: Shay
authors.affiliation: Astellas Pharma Global Development, Northbrook, Illinois.
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.affiliation: Astellas Pharma Global Development, Northbrook, Illinois.
authors.forename: J P
authors.initials: JP
authors.lastname: Garg
authors.affiliation: ARS Rheumatica, Warsaw, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Zubrzycka-Sienkiewicz
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D009536:Niacinamide; D053612:Janus Kinases; C000608065:peficitinib; D000218:Adamantane; D008727:Methotrexate